1.138SEK-14.82%Mkt Cap: 385.80M SEKP/E: —Last update: 2026-05-13
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against strept…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-1.38
PEG—
P/B1.62
P/S20.23
EV/EBITDA-2.77
EV/Revenue13.88
EPS (TTM)-0.27
EPS (Forward)-0.82
Cash Flow & Leverage
FCF Yield-10.12%
FCF Margin-204.66%
Operating CF-65.79M SEK
CapEx (TTM)1.13M SEK
Net Debt/EBITDA1.52
Net Debt-145.27M SEK
Technical
SMA 500.9721 (+17.1%)
SMA 2000.9546 (+19.2%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)599.41K
Avg Vol (10d)867.08K
Technical Indicators
RSI (14)52.1
MACD0.0843
MACD Signal0.0871
MACD Hist.-0.0028
BB Upper1.361 SEK
BB Middle1.175 SEK
BB Lower0.9881 SEK
BB Width31.78%
ATR (14)0.1203 SEK
Vol Ratio (20d)1.88x
52W Range
0.572064% of range1.462
52W High1.462 SEK
52W Low0.5720 SEK
Profitability
Gross Margin-57.18%
EBITDA Margin0.00%
Profit Margin-402.32%
Oper. Margin-525.61%
ROE-29.40%
ROA-27.45%
Revenue Growth-7.50%
Earnings Growth—
Balance Sheet
Debt/Equity0.00
Current Ratio6.46
Quick Ratio6.06
Book Value/Sh0.6990 SEK
Cash/Share0.4020 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.340.81M
Float210.48M
Insiders19.34%
Institutions34.37%
Analyst Consensus
Rating—
Target (Mean)2.200 SEK
Target Range2.200 SEK – 2.200 SEK
# Analysts1
Company
Market Cap385.80M SEK
Enterprise Value264.59M SEK
Revenue (TTM)19.07M SEK
Gross Profit-11.49M SEK
Net Income (TTM)-80.81M SEK
Revenue/Share0.0550 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
Last Price1.138 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—